Loading...
 
Translate Register Log In Login with facebookLogin and Register

Blood cell cancer is associated with a 3X worse Vitamin D Receptor – June 2019

Vitamin D receptor gene polymorphism is associated with multiple myeloma

J of Cellular Biochemistry https://doi.org/10.1002/jcb.29135
Hongbing Rui Ying Liu Meiying Lin Xiaoqiang Zheng

VitaminDWiki

It is unknown if Blood Cell Cancer ==> Poor VDR or Poor VDR ==> Blood Cell Cancer

Vitamin D Receptor and Cancers

Items in both categories Vitamin D Receptor and Cancer - Breast:

Items in both categories Vitamin D Receptor and Cancer - Colon:

Items in both categories Vitamin D Receptor and Cancer

Items in both categories Vitamin D Receptor and Cancer - other:

Items in both categories Vitamin D Receptor and Cancer - Skin:

Items in both categories Vitamin D Receptor and Cancer - Prostate:

Items in both categories Vitamin D Receptor and Cancer - Lung:


Objectives: The aim of this study was to explore the Vitamin D receptor (VDR) gene polymorphism and its association with multiple myeloma (MM) development.

Methods
The peripheral blood of 40 MM cases and 84 healthy controls were collected. Polymerase chain reaction (PCR) and DNA sequencing were applied to detect VDR gene polymorphism (including: FokI, BsmI, ApaI, and TaqI). SHESIS biological information software was used to analyze genotypes, alleles, linkage disequilibrium (LD), haplotype distribution, and their association with MM.

Results
Compared with controls, the MM group had a significantly higher frequency of the A allele in

  • BsmI site (8.7% vs 2.4%) and
  • C allele in the TaqI site (10.5% vs 3.6%).

These two alleles were closely associated with an increased risk of MM (P = .025; P = .030). The highly rare genotypes (BsmI‐AA and TaqI‐CC) were found in one patient with MM.

Conclusion: VDR gene polymorphisms may be a molecular marker of MM risk.

Created by admin. Last Modification: Friday June 14, 2019 00:22:49 GMT-0000 by admin. (Version 2)
See any problem with this page? Report it (FINALLY WORKS)